Pronunciation: ev-RIZ-dee
Generic name: risdiplam
Dosage form: oral solution (60 mg for constitution to provide 0.75 mg/mL solution), oral tablet (5 mg)
Drug class: Miscellaneous uncategorized agents

Medically reviewed by Carmen Pope, BPharm. Last updated on Feb 18, 2025.

What is Evrysdi?

Evrysdi is used to treat spinal muscular atrophy (SMA) in children and adults and is available as an oral solution and tablets.

Evrysdi works by activating a gene in the body called SMN2, which then produces more of an important protein that muscles and nerves need to work properly. By increasing this protein throughout the brain, spinal cord, and body, Evrysdi helps improve muscle strength and movement in both children and adults with SMA. See How does Evrysdi work? for more information.

Evrysdi oral solution gained FDA approval on August 7, 2020. The oral tablets were FDA approved on February 12, 2025, based on results of a bioequivalence study, which demonstrated comparable efficacy between the 5 mg tablet, whether swallowed whole or dispersed in filtered water, and the same dose of the oral solution.

Before taking Evrysdi

Before taking Evrysdi, tell your healthcare provider about all of your medical conditions, including if you:

• have liver problems.
• are pregnant or plan to become pregnant. If you are pregnant, or are planning to become pregnant, ask your healthcare provider for advice before taking this medicine. Evrysdi may harm your unborn baby.
• are a woman who can become pregnant
• are an adult male planning to have children
• are breastfeeding or plan to breastfeed. 

Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements. Keep a list of them to show your healthcare provider and pharmacist when you get a new medicine.

Pregnancy and fertility

Before you start your treatment with Evrysdi, your healthcare provider may test you for pregnancy. Because Evrysdi may harm your unborn baby, you and your healthcare provider will decide if taking Evrysdi is right for you during this time.

Talk to your healthcare provider about birth control methods that may be right for you. Use birth control while on treatment and for at least 1 month after stopping.

There is a pregnancy exposure registry that monitors pregnancy and birth outcomes in women exposed to Evrysdi during pregnancy. Healthcare providers are encouraged to register patients and pregnant women are encouraged to register themselves by calling 1-833- 760-1098 or visiting https://www.evrysdipregnancyregistry.com.

Evrysdi may affect a man’s ability to have children (fertility). If this is of concern to you, make sure to ask a healthcare provider for advice.

Breastfeeding

It is not known if Evrysdi passes into breast milk and may harm your baby. If you plan to breastfeed, discuss with your healthcare provider about the best way to feed your baby while on treatment.

How should I take Evrysdi?

See the detailed Instructions for Use that comes with your prescription for information on how to take or give Evrysdi.

• Evrysdi liquid solution is prepared by your pharmacist. If the medicine in the bottle is a powder, do not use it. Contact your pharmacist for a replacement. This is given by mouth or through a feeding tube.
• Evrysdi oral tablets can be swallowed whole or dispersed in filtered or unchlorinated water.
• Avoid getting Evrysdi on your skin or in your eyes. If Evrysdi gets on your skin, wash the area with soap and water. If Evrysdi gets in your eyes, rinse your eyes with water.

Taking Evrysdi

• Your healthcare provider will tell you how long you or your child needs to take Evrysdi. Do not stop treatment unless your healthcare provider tells you to.
• For infants and children, your healthcare provider will determine the daily dose of Evrysdi needed based on your child’s age and weight. For adults, take 5 mg of Evrysdi daily.
  • Take Evrysdi exactly as your healthcare provider tells you to take it. Do not change the dose without talking to your healthcare provider.
• The Evrysdi oral tablet may be swallowed whole or dispersed in non-chlorinated drinking water (e.g., filtered water).
• Take Evrysdi 1 time daily after a meal (or after breastfeeding for a child) at approximately the same time each day. Drink water afterwards to make sure Evrysdi has been completely swallowed.
• Do not mix liquid Evrysdi with formula or milk.
• If you are unable to swallow and have a nasogastric or gastrostomy tube, Evrysdi can be given through the tube as a liquid.
• If you miss a dose of Evrysdi:
  • If you remember the missed dose within 6 hours of when you normally take Evrysdi, then take or give the dose. Continue taking Evrysdi at your usual time the next day.
  • If you remember the missed dose more than 6 hours after you normally take Evrysdi, skip the missed dose. Take your next dose at your usual time the next day.
• If you do not fully swallow the dose, or you vomit after taking a dose, do not take another dose to make up for that dose. Wait until the next day to take the next dose at your usual time.

Reusable oral syringes for oral solution

• Your pharmacist will provide you with the reusable oral syringes that are needed for taking your liquid Evrysdi and explain how to use them. Wash the syringes per instructions after use. Do not throw them away.
• Use the reusable oral syringes provided by your pharmacist (you should receive 2 identical oral syringes) to measure your or your child’s dose of Evrysdi, as they are designed to protect the medicine from light. Contact your healthcare provider or pharmacist if your oral syringes are lost or damaged.
• Once transferred from the bottle to the oral syringe, take Evrysdi right away. Do not store the solution in the syringe. If Evrysdi is not taken within 5 minutes of when it is drawn up, Evrysdi should be thrown away from the reusable oral syringe, and a new dose should be prepared.

Evrysdi side effects

The most common side effects include:

• For later-onset SMA:
  • fever
  • diarrhea
  • rash.
• For infantile-onset SMA:
  • fever
  • runny nose, sneezing, sore throat, and cough (upper respiratory infection)
  • constipation
  • diarrhea
  • lung infection
  • vomiting
  • rash.

These are not all of the possible side effects. For more information, ask your healthcare provider or pharmacist. Call your doctor for medical advice about side effects. You may report side effects to the FDA at 1-800-FDA-1088.

Related/similar drugs

How should I store Evrysdi?

Keep all Evrysdi products and syringes out of the reach of children.

Evrysdi oral solution

• Store in the refrigerator between 36°F to 46°F (2°C to 8°C). Do not freeze.
• Keep in an upright position in the original amber bottle to protect from light.
• Throw away (discard) any unused portion of Evrysdi 64 days after it is mixed by the pharmacist (constitution). Please see the Discard After date written on the bottle label. (See the Instructions for Use that comes with Evrysdi).

Evrysdi oral tablets

• Store at room temperature between 68°F to 77°F (20°C to 25°C).
• Keep the bottle tightly closed to protect the tablets from moisture.

What are the ingredients in Evrysdi?

Active ingredient: risdiplam
Inactive ingredients (Evrysdi oral solution): ascorbic acid, disodium edetate dihydrate, isomalt, mannitol, polyethylene glycol 6000, sodium benzoate, strawberry flavor, sucralose, and tartaric acid.

Inactive ingredients (Evrysdi oral tablets): colloidal silicon dioxide, crospovidone, mannitol, microcrystalline cellulose, polyethylene glycol 3350, polyvinyl alcohol, sodium stearyl fumarate, strawberry flavor, talc, tartaric acid, titanium dioxide, and yellow iron oxide.

Who makes Evrysdi?

Genentech, Inc., a member of the Roche Group, based in South San Francisco, CA, makes Evrysdi.

Popular FAQ

View more FAQ

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer